FutureChem Co.Ltd Total Liabilities
FutureChem Co.Ltd total liabilities. Based on the latest financial reports, FutureChem Co.Ltd (220100) has total liabilities worth ₩16.93 Billion KRW (≈ $11.47 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check FutureChem Co.Ltd liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of FutureChem Co.Ltd (2016–2025)
Total liabilities of FutureChem Co.Ltd from 2016 to 2025. This chart illustrates how FutureChem Co.Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore FutureChem Co.Ltd strategic investment ratio to see how much of total assets are deployed in long-term investments.
FutureChem Co.Ltd Competitors by Total Liabilities
The table below lists competitors of FutureChem Co.Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Maxigen Biotech Inc
TW:1783
|
Taiwan | NT$534.02 Million |
|
Ester Industries Limited
NSE:ESTER
|
India | Rs8.91 Billion |
|
Taseco Air Services JSC
VN:AST
|
Vietnam | ₫298.09 Billion |
|
TMT Investments PLC
LSE:TMT
|
UK | $661.36K |
|
Ubiquoss Inc
KQ:264450
|
Korea | ₩33.78 Billion |
|
DAEYANG ELECTRIC.Co.Ltd
KQ:108380
|
Korea | ₩68.47 Billion |
|
Alcidion Group Ltd
AU:ALC
|
Australia | AU$27.82 Million |
Liability Composition Analysis (2016–2025)
This chart breaks down FutureChem Co.Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see total assets of FutureChem Co.Ltd.
Liquidity & Leverage Metrics
FutureChem Co.Ltd Total Liabilities Ratios Explained
FutureChem Co.Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.54 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.32 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.24 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how FutureChem Co.Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for FutureChem Co.Ltd (2016–2025)
The table below shows the annual total liabilities of FutureChem Co.Ltd from 2016 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | ₩19.70 Billion ≈ $13.35 Million |
-1.71% |
| 2024-12-31 | ₩20.04 Billion ≈ $13.58 Million |
+124.71% |
| 2023-12-31 | ₩8.92 Billion ≈ $6.04 Million |
-52.00% |
| 2022-12-31 | ₩18.58 Billion ≈ $12.59 Million |
-23.91% |
| 2021-12-31 | ₩24.42 Billion ≈ $16.55 Million |
-37.52% |
| 2020-12-31 | ₩39.08 Billion ≈ $26.49 Million |
-24.91% |
| 2019-12-31 | ₩52.05 Billion ≈ $35.27 Million |
+9.37% |
| 2018-12-31 | ₩47.59 Billion ≈ $32.25 Million |
+440.85% |
| 2017-12-31 | ₩8.80 Billion ≈ $5.96 Million |
+458.64% |
| 2016-12-31 | ₩1.58 Billion ≈ $1.07 Million |
-- |
About FutureChem Co.Ltd
FutureChem Co.,Ltd engages in the research and development, production, and sale of chemicals, pharmaceuticals, and medical devices in South Korea and internationally. The company offers radioactive pharmaceuticals, including [18F]FDG for the treatment of general cancer diagnosis, PDvue for Parkinson's disease, Alzavue for Alzheimer's disease, and FLT for the lung cancer diagnosis. Its products i… Read more